All In Biotech

Drug Trial Radar · NCT02293265

Cross-sectional Study for Identification and Description of Severe Asthma Patients

Identification and Description of Severe Asthma Patients in a Cross-sectional Study-the IDEAL Study

Last checked: Nov 20, 2026Latest source record: Apr 4, 2016 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

767

Actual

Start

Dec 2014

Primary completion

May 2015

Study completion May 2015

Sponsor

Lead sponsor
GlaxoSmithKlineGSK (GSK)
Sponsor type
Industry
First posted
Nov 18, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Who can join
All sexes, from 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This will be a non-drug interventional cross-sectional study, where the screening visit and study visit can occur on the same day. Investigational product will not be administered. Approximately 790 subjects with severe asthma will be screened to achieve a total of at least 750 evaluable study subjects. The study will not include a run-in or follow-up period. This study will provide a more reliable description of the severe asthma patient landscape with respect to the potential eligibility for treatment with mepolizumab, omalizumab, and reslizumab. This study aims to estimate the potential overlap of patients eligible for treatment with mepolizumab and those eligible for treatment with omalizumab and/or reslizumab. Additionally, the current study will also ascertain and describe reslizumab eligibility with respect to both mepolizumab and omalizumab, in the severe asthma patient population.

Conditions

  • Asthma

Interventions

  • Short Acting Beta Agonist (SABA)Drug

    Participants requiring a spirometry measurement will be administered a SABA in a metered dose inhaler (MDI) during the reversibility assessments

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of severe asthma patients eligible for one or more biologic treatments for asthmaTime frame: Day 1

Locations

74 sites in 6 countries. Site status is shown where the registry gives one.

  • GSK Investigational Site

    Little Rock, Arkansas

  • GSK Investigational Site

    Fresno, California

  • GSK Investigational Site

    Los Angeles, California

  • GSK Investigational Site

    Newport Beach, California

  • GSK Investigational Site

    Riverside, California

  • GSK Investigational Site

    Rolling Hills Estates, California

  • GSK Investigational Site

    San Diego, California

  • GSK Investigational Site

    Upland, California

  • GSK Investigational Site

    Tallahassee, Florida

  • GSK Investigational Site

    Owensboro, Kentucky

  • GSK Investigational Site

    Baltimore, Maryland

  • GSK Investigational Site

    Columbia, Maryland

  • GSK Investigational Site

    Minneapolis, Minnesota

  • GSK Investigational Site

    Plymouth, Minnesota

  • GSK Investigational Site

    Corning, New York

  • GSK Investigational Site

    Charlotte, North Carolina

  • GSK Investigational Site

    Shelby, North Carolina

  • GSK Investigational Site

    Cincinnati, Ohio

  • GSK Investigational Site

    Medford, Oregon

  • GSK Investigational Site

    Pittsburgh, Pennsylvania

  • GSK Investigational Site

    Greenville, South Carolina

  • GSK Investigational Site

    Coffs Harbour, New South Wales, Australia

  • GSK Investigational Site

    Sherwood Park, Alberta, Canada

  • GSK Investigational Site

    Brampton, Ontario, Canada

  • GSK Investigational Site

    Burlington, Ontario, Canada

  • GSK Investigational Site

    Grimsby, Ontario, Canada

  • GSK Investigational Site

    London, Ontario, Canada

  • GSK Investigational Site

    Mississauga, Ontario, Canada

  • GSK Investigational Site

    St-Charles-Borromée, Ontario, Canada

  • GSK Investigational Site

    Toronto, Ontario, Canada

  • GSK Investigational Site

    Toronto, Ontario, Canada

  • GSK Investigational Site

    Windsor, Ontario, Canada

  • GSK Investigational Site

    Montreal, Quebec, Canada

  • GSK Investigational Site

    Québec, Quebec, Canada

  • GSK Investigational Site

    Québec, Quebec, Canada

  • GSK Investigational Site

    Trois-Rivières, Quebec, Canada

  • GSK Investigational Site

    Bayonne, France

  • GSK Investigational Site

    Dijon, France

  • GSK Investigational Site

    Grenoble, France

  • GSK Investigational Site

    Lille, France

Showing 40 of 74 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.